OCRX Profile
Ocera
Therapeutics, Inc., with the ticker symbol OCRX, is a
biopharmaceutical company that focuses on developing and
commercializing therapies for the treatment of gastrointestinal and
liver diseases. The company's lead product candidate is OCR-002, which
is being developed as a treatment for hepatic encephalopathy, a
neurological disorder that can occur in patients with liver disease.
Here's an extended company report for Ocera Therapeutics, Inc.:
Ocera Therapeutics, Inc. was founded in 2005 and is headquartered
in Palo Alto, California. The company focuses on developing and
commercializing therapies for the treatment of gastrointestinal and
liver diseases.
Ocera's lead product candidate is OCR-002,
which is being developed as a treatment for hepatic encephalopathy, a
neurological disorder that can occur in patients with liver disease.
OCR-002 is a proprietary formulation of ornithine phenylacetate, a
molecule that can help reduce the levels of toxic substances in the
blood that can cause hepatic encephalopathy.
In addition to
OCR-002, Ocera is also developing other product candidates for the
treatment of gastrointestinal and liver diseases, including OCR-003
for the treatment of hyperammonemia and OCR-013 for the treatment of
nonalcoholic steatohepatitis.
As of March 18, 2023, Ocera
Therapeutics, Inc. had a market capitalization of approximately $20
million. The company's revenue for the year ended December 31, 2021,
was $0.5 million, a decrease compared to the previous year. The
company has reported net losses in recent years, reflecting the
challenges of developing and commercializing new pharmaceutical
products.
Ocera Therapeutics, Inc. operates in a highly
competitive industry and faces risks associated with the clinical
development and commercialization of new pharmaceutical products. The
company's future growth will depend on its ability to successfully
complete clinical trials, obtain regulatory approvals, and
successfully commercialize its products.
In conclusion, Ocera
Therapeutics, Inc. is a biopharmaceutical company that focuses on
developing and commercializing therapies for the treatment of
gastrointestinal and liver diseases. The company's lead product
candidate, OCR-002, is being developed as a treatment for hepatic
encephalopathy. While the company faces challenges associated with
developing and commercializing new pharmaceutical products, its
pipeline of product candidates demonstrates its potential for
continued growth and success in
|
